Skip to main content
Publish date:

Compugen To Present At The Morgan Stanley 19th Annual Global Healthcare Conference

HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd.

HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (CGEN) - Get Compugen Ltd. Report, a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Morgan Stanley 19 th Annual Global Healthcare Conference (virtual), on Thursday, September 9, 2021 at 11:00 am ET.

A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at A replay will be available following the live event.

About Compugen  

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combination. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at

Company contact:   Yvonne Naughton, PhD  Head of Investor Relations and Corporate CommunicationsEmail:  Tel: +1 (628) 241-0071  

Investor Relations contact: John Mullaly LifeSci Advisors, LLC Email:   Tel: +1 (617) 429-3548

View original content:

SOURCE Compugen Ltd.